Serious adverse events less likely with mycophenolate mofetil, too, study finds
A newer immune-suppressing drug called mycophenolate mofetil (CellCept) is better at controlling a serious kidney complication from lupus than another commonly used therapy, a new study suggests.
Full story | New England Journal of Medicine study